Eli Lilly and Co. is considering Houston as a location for one of its four planned new U.S. manufacturing sites, with the Texas city potentially landing a $5.9 billion facility that could employ more than 600, according to reports.
If built, Lilly would use the 236-acre site in Houston’s new Generation Park development site to manufacture active pharmaceutical ingredients, or APIs, according to a tax incentive application filed with the state of Texas.
Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment. The plants are expected to create 3,000 long-term jobs and nearly 10,000 construction positions during the buildout. Three of the four new Lilly sites will focus on manufacturing APIs.
A Lilly spokesperson on Tuesday said the company has received “numerous inquiries and submissions” but did not provide details on the potential expansion in Texas.
“Lilly is actively evaluating manufacturing site locations throughout the U.S. to expand capacity to meet the growing demand for our current and future pipeline medicines across multiple therapeutic areas,” Lilly said in an emailed statement. “Any future decisions will be shared at the appropriate time.”
In the filing, the company said the project could employ about 604 full-time employees with positions including operations technicians, production specialists, maintenance support, quality control and assurance, engineering, administration and management.
The potential project also could result in more than 2,100 construction jobs.
Driven by strong sales of medications including weight-loss treatment Zepbound and diabetes treatment Mounjaro, Lilly has made capital expansion commitments in the United States totaling more than $50 billion since 2020.
Those projects include new sites at the LEAP Lebanon Innovation District in Boone County. Lilly recently broke ground on its $4.5 billion Lilly Medicine Foundry in the LEAP district.
The company also has made expansions and updates to several different manufacturing facilities in Indianapolis.
APIs are used to make two of Lilly’s blockbuster medications—diabetes treatment Mounjaro and weight-loss treatment Zepbound—which are in heavy demand amid growing usage. The two drugs accounted for more than one-third of the drugmaker’s record $45 billion in revenue in 2024.
Copyright © 2025 All Rights Reserved.